Clinical Trials Directory

Trials / Completed

CompletedNCT00193388

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
100 (planned)
Sponsor
SCRI Development Innovations, LLC · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer

Detailed description

Upon determination of eligibility, all patients will be receive: * Topotecan

Conditions

Interventions

TypeNameDescription
DRUGTopotecan

Timeline

Start date
2002-09-01
Primary completion
2004-12-01
Completion
2007-02-01
First posted
2005-09-19
Last updated
2010-07-28

Source: ClinicalTrials.gov record NCT00193388. Inclusion in this directory is not an endorsement.